Drug:
Reaction: DISEASE PROGRESSION
20250101 - 20251231
No. 401 - 500
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 401 | 25062999 |
US |
86 | 2 |
Disease progression, Oedema peripheral, Off label use, |
||||
GEMCITABINE HYDROCHLORIDE, GEMCITABINE, |
||||
| 402 | 25063001 |
CN |
56 | 2 |
Disease progression, |
||||
LEUCOVORIN CALCIUM, CARBOPLATIN, CAPECITABINE, CISPLATIN, OXALIPLATIN, BEVACIZUMAB, PACLITAXEL, FLUOROURACIL, |
||||
| 403 | 25063063 |
US |
50 | 2 |
Disease progression, Autoimmune haemolytic anaemia, |
||||
CARBOPLATIN, ETOPOSIDE, ATEZOLIZUMAB, |
||||
| 404 | 25063064 |
US |
64 | 2 |
Disease progression, |
||||
GEMCITABINE HYDROCHLORIDE, GEMCITABINE, DOCETAXEL, DOCETAXEL ANHYDROUS, CISPLATIN, |
||||
| 405 | 25063075 |
TR |
41 | 1 |
Disease progression, |
||||
TEMOZOLOMIDE, |
||||
| 406 | 25063079 |
TR |
37 | 1 |
Disease progression, |
||||
DEXAMETHASONE, DEXAMETHASONE 1.5 MG, |
||||
| 407 | 25063213 |
CA |
||
Hernia, Disease progression, Off label use, |
||||
RITUXIMAB, RITUXIMAB, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE, DIPHENHYDRAMINE HYDROCHLORIDE, METHYLPREDNISOLONE ACETATE, |
||||
| 408 | 25063362 |
NO |
60 | |
Disease progression, |
||||
BRIGATINIB, |
||||
| 409 | 25063407 |
US |
54 | 2 |
Tricuspid valve incompetence, Disease progression, Intravenous leiomyomatosis, |
||||
PROGESTERONE, |
||||
| 410 | 25063426 |
US |
30 | 2 |
Graft versus host disease in eye, Disease progression, Chronic graft versus host disease in lung, Condition aggravated, Off label use, |
||||
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE, SODIUM CHLORIDE, SODIUM CHLORIDE, BELUMOSUDIL, BELUMOSUDIL, RUXOLITINIB, RUXOLITINIB, ABATACEPT, ABATACEPT, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, |
||||
| 411 | 25063646 |
PL |
57 | 1 |
Disease progression, |
||||
PIRFENIDONE, |
||||
| 412 | 25063691 |
PL |
72 | 2 |
Electrocardiogram QT prolonged, Disease progression, Ascites, Gastric ulcer, Oedema peripheral, Dyspepsia, |
||||
IVOSIDENIB, IVOSIDENIB, BISOPROLOL FUMARATE, |
||||
| 413 | 25063904 |
|||
Drug ineffective, Disease progression, Acute myeloid leukaemia, |
||||
| 414 | 25063908 |
FR |
63 | 2 |
Enterocolitis, Disease progression, Malignant neoplasm progression, Drug ineffective, Mucosal inflammation, |
||||
AZACITIDINE, AZACITIDINE FOR, HYDROXYUREA, LENALIDOMIDE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, ERYTHROPOIETIN, TREOSULFAN, THIOTEPA, ETOPOSIDE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE, BUSULFAN, (DAUNORUBICIN AND CYTARABINE) LIPOSOME, (DAUNORUBICIN AND CYTARABINE) LIPOSOME, (DAUNORUBICIN AND CYTARABINE) LIPOSOME, CYCLOSPORINE, ACYCLOVIR, POSACONAZOLE, POSACONAZOLE DELAYED-RELEASE, RUXOLITINIB, PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, BUSULFAN, BUSULFAN, |
||||
| 415 | 25063922 |
IT |
73 | 2 |
Disease progression, Subdural haematoma, Escherichia infection, Staphylococcal infection, |
||||
AZACITIDINE, AZACITIDINE FOR, VENETOCLAX, VENETOCLAX, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, ACYCLOVIR, PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, CALCIUM, CALCIUM, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, PREGABALIN, MORPHINE, DAPTOMYCIN, DAPTOMYCIN, MEROPENEM, MEROPENEM, NYSTATIN, NYSTATIN OINTMENT, NYSTATIN CREAM, FUROSEMIDE, FUROSEMIDE, FUROSEMIDE, FUROSEMIDE, FUROSEMIDE, LINEZOLID, SERTRALINE HYDROCHLORIDE, ALLOPURINOL, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, LORAZEPAM, POSACONAZOLE, POSACONAZOLE DELAYED-RELEASE, MIDAZOLAM, MIDAZOLAM HYDROCHLORIDE, PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, PHYTONADIONE, PHYTONADIONE, PANTOPRAZOLE, SODIUM BICARBONATE, SODIUM BICARBONATE INJECTION,, SODIUM BICARBONATE, SODIUM BICARBONATE INJECTION,, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, INSULIN GLULISINE, INSULIN GLULISINE, INSULIN GLULISINE, INSULIN GLULISINE, INSULIN GLULISINE, INSULIN GLULISINE, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, LEVOTHYROXINE, |
||||
| 416 | 25064180 |
CH |
18 | 1 |
Disease progression, Drug ineffective for unapproved indication, Off label use, |
||||
ETOPOSIDE, ETOPOSIDE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, BRENTUXIMAB VEDOTIN, BRENTUXIMAB VEDOTIN, BRENTUXIMAB VEDOTIN, BRENTUXIMAB VEDOTIN, CARMUSTINE, CARMUSTINE, CYTARABINE, CYTARABINE, MELPHALAN, MELPHALAN, PEMBROLIZUMAB, BENDAMUSTINE HCL, NIVOLUMAB, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, VINORELBINE, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, THIOTEPA, THIOTEPA, FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE, TREOSULFAN, TREOSULFAN, IBRUTINIB, DOXORUBICIN HYDROCHLORIDE, BLEOMYCIN, BLEOMYCIN SULFATE, DACARBAZINE, IFOSFAMIDE, CARBOPLATIN, |
||||
| 417 | 25065183 |
AU |
1 | |
Disease progression, Therapy cessation, |
||||
LURBINECTEDIN, |
||||
| 418 | 25065226 |
CA |
70 | 1 |
Disease progression, |
||||
VENETOCLAX, VENETOCLAX, VENETOCLAX, VENETOCLAX, VENETOCLAX, VENETOCLAX, VENETOCLAX, HYDROXYUREA, LEVOFLOXACIN, LEVOFLOXACIN IN 5% DEXTROSE, FAMOTIDINE, CALCIUM, METRONIDAZOLE, SUCRALFATE, SUCRALFATE ORAL SUSPENSION, SUCRALFATE ORAL, IVERMECTIN, PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM, PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, IPRATROPIUM BROMIDE, MONTELUKAST, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CALCIUM GLUCONATE, AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, MAGNESIUM OXIDE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, FILGRASTIM, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, MEROPENEM, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, MELATONIN, SENNOSIDES, SENNA LEAF, SENNA, SENNOSIDES 8.6 MG TABLETS, METOCLOPRAMIDE HYDROCHLORIDE, |
||||
| 419 | 25065442 |
CZ |
2 | |
Disease progression, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 420 | 25065446 |
CZ |
2 | |
Disease progression, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 421 | 25065902 |
CN |
||
Disease progression, |
||||
DURVALUMAB, |
||||
| 422 | 25056629 |
NZ |
75 | 2 |
Disease progression, Off label use, |
||||
BEVACIZUMAB, AFLIBERCEPT, |
||||
| 423 | 25056656 |
VN |
||
Disease progression, |
||||
DURVALUMAB, |
||||
| 424 | 25056698 |
CA |
48 | 1 |
Neovascular age-related macular degeneration, Disease progression, |
||||
RANIBIZUMAB, |
||||
| 425 | 25056879 |
CN |
81 | 1 |
Toxic epidermal necrolysis, Disease progression, |
||||
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN, MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, AMINOPHYLLINE, |
||||
| 426 | 25057094 |
PL |
39 | 1 |
Neutropenia, Tumour lysis syndrome, COVID-19, Rash macular, Disease progression, |
||||
OBINUTUZUMAB, RITUXIMAB, MOSUNETUZUMAB, MOSUNETUZUMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN, PREDNISONE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, CYTARABINE, CISPLATIN, |
||||
| 427 | 25057167 |
HU |
42 | 2 |
Disease progression, |
||||
POLATUZUMAB VEDOTIN, RITUXIMAB, BENDAMUSTINE HCL, |
||||
| 428 | 25057192 |
US |
2 | |
Death, Immune effector cell-associated neurotoxicity syndrome, Disease progression, Performance status decreased, Asthenia, Cytokine release syndrome, Tachycardia, Chills, Hypotension, Vomiting, Pyrexia, Nausea, |
||||
TEBENTAFUSP, TEBENTAFUSP, TEBENTAFUSP, TEBENTAFUSP, TEBENTAFUSP, TEBENTAFUSP, APIXABAN, CYANOCOBALAMIN, TOBRAMYCIN / DEXAMETHASONE, FUROSEMIDE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CONTINUOUS SPRAY, ANTI-PRURITIC, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, HYDROCORTISONE LOTION KIT, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE CREAM 1%, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CONTINUOUS SPRAY, ANTI-PRURITIC, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, HYDROCORTISONE LOTION KIT, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE CREAM 1%, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, INSULIN LISPRO, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, SERTRALINE, VALSARTAN, |
||||
| 429 | 25057294 |
CA |
45 | 2 |
Multiple sclerosis, Condition aggravated, Disease progression, |
||||
OCRELIZUMAB, |
||||
| 430 | 25057309 |
CN |
73 | 2 |
Disease progression, |
||||
GLOFITAMAB, |
||||
| 431 | 25057620 |
TR |
2 | |
Disease progression, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 432 | 25057838 |
LB |
||
Disease progression, |
||||
ATEZOLIZUMAB, |
||||
| 433 | 25057876 |
IT |
69 | 1 |
Disease progression, |
||||
ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, |
||||
| 434 | 25058881 |
US |
36 | 2 |
Disease progression, Drug ineffective, |
||||
TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, AZACITIDINE, AZACITIDINE FOR, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CLOFARABINE, CLOFARABINE, DECITABINE, VENETOCLAX, |
||||
| 435 | 25058890 |
IT |
43 | 2 |
Disease progression, Drug ineffective, |
||||
OXALIPLATIN, FLUOROURACIL, FLUOROURACIL, FLUOROURACIL, BEVACIZUMAB, BEVACIZUMAB, AFLIBERCEPT, |
||||
| 436 | 25058922 |
CZ |
2 | |
Disease progression, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 437 | 25058995 |
US |
1 | |
Disease progression, |
||||
PEXIDARTINIB HYDROCHLORIDE, |
||||
| 438 | 25059280 |
DE |
31 | 2 |
Drug ineffective, Disease progression, |
||||
DOXORUBICIN, CARBOPLATIN, |
||||
| 439 | 25059302 |
FR |
12 | 2 |
Drug ineffective for unapproved indication, Disease progression, Fatigue, Off label use, |
||||
ETOPOSIDE, AXITINIB, |
||||
| 440 | 25059359 |
FR |
||
Gastroduodenal ulcer, Disease progression, Hepatotoxicity, Device related thrombosis, Metastasis, Device related sepsis, Cholangitis, Metastases to liver, Complication of device insertion, Systemic toxicity, Catheter site inflammation, Device leakage, Device related infection, Arteritis, Catheter site haematoma, Off label use, Wound dehiscence, General physical health deterioration, |
||||
BEVACIZUMAB, PANITUMUMAB, |
||||
| 441 | 25059418 |
AU |
63 | 2 |
Portal hypertension, Disease progression, Hepatic cirrhosis, Intestinal atony, |
||||
| 442 | 25059543 |
JP |
2 | |
Disease progression, Infusion related reaction, Therapeutic product effect incomplete, |
||||
PEMBROLIZUMAB, ENFORTUMAB VEDOTIN, |
||||
| 443 | 25059753 |
IT |
2 | |
Disease progression, Off label use, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 444 | 25059883 |
US |
73 | |
Anaemia, Deep vein thrombosis, Underdose, Product dose omission issue, Inappropriate schedule of product administration, Disease progression, |
||||
OLAPARIB, TAMSULOSIN HYDROCHLORIDE, |
||||
| 445 | 25059884 |
US |
||
Disease progression, |
||||
AVAPRITINIB, |
||||
| 446 | 25059887 |
ES |
72 | 2 |
Pulmonary embolism, Deep vein thrombosis, Disease progression, Ascites, Intestinal obstruction, Metastases to peritoneum, Metastases to muscle, |
||||
LETROZOLE, LETROZOLE TABLETS, RIPRETINIB, |
||||
| 447 | 25060285 |
MY |
52 | 2 |
Multiple organ dysfunction syndrome, Disease progression, Drug ineffective, |
||||
PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, MEROPENEM, MEROPENEM, MEROPENEM, MEROPENEM, |
||||
| 448 | 25060671 |
RO |
54 | 1 |
Metastases to spine, Lymphadenopathy, Disease progression, |
||||
CEMIPLIMAB-RWLC, |
||||
| 449 | 25063206 |
67 | 1 | |
Disease progression, Mantle cell lymphoma, |
||||
PIRTOBRUTINIB, |
||||
| 450 | 25055297 |
US |
64 | 1 |
Disease progression, Drug ineffective, |
||||
DOCETAXEL, DOCETAXEL ANHYDROUS, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, CISPLATIN, |
||||
| 451 | 25048796 |
CA |
61 | 1 |
Asthenia, Abdominal discomfort, Vision blurred, Chest discomfort, Dyspnoea, Nocturia, Osteoarthritis, Metastases to pancreas, Tumour thrombosis, Cyst, Therapy partial responder, Nausea, Flatulence, Anxiety, Disease progression, Decreased appetite, Hepatic lesion, Iron deficiency, Cataract, Fatigue, Asthenia, Abdominal pain, Metastatic lymphoma, Constipation, |
||||
TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, LENVATINIB, ALENDRONATE SODIUM, ALENDRONATE SODIUM TABLET, ESCITALOPRAM, ESCITALOPRAM OXALATE, ESCITSLOPRAM, IRON, RABEPRAZOLE, TRIMETHOPRIM, PANTOPRAZOLE, CALCIUM, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, POLYETHYLENE GLYCOL (3350), POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 400, SENNOSIDES, SENNA LEAF, SENNA, SENNOSIDES 8.6 MG TABLETS, LACTULOSE, METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, OLANZAPINE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, LORAZEPAM, METHYLPHENIDATE, METHYLPHENIDATE HYDROCHLORIDE, FENTANYL, CABOZANTINIB, DIMENHYDRINATE, STANDARDIZED SENNA CONCENTRATE, METHYLPREDNISOLONE SODIUM SUCCINATE, |
||||
| 452 | 25049732 |
DE |
1 | |
Disease progression, |
||||
ABIRATERONE ACETATE, ABIRATERONE, DOCETAXEL, DOCETAXEL ANHYDROUS, |
||||
| 453 | 25049734 |
JP |
65 | 1 |
Acute leukaemia, Disease progression, Disease recurrence, |
||||
MELPHALAN, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, AZACITIDINE, AZACITIDINE FOR, MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE, CYTARABINE, VENETOCLAX, |
||||
| 454 | 25049768 |
TR |
38 | 2 |
Disease progression, |
||||
CAPECITABINE, CISPLATIN, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, LAPATINIB, TRASTUZUMAB, |
||||
| 455 | 25049769 |
CO |
61 | 2 |
Necrosis, Disease progression, Drug hypersensitivity, Raynaud^s phenomenon, Disease recurrence, Vaginal haemorrhage, |
||||
GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, CISPLATIN, CISPLATIN, CARBOPLATIN, PACLITAXEL, SILDENAFIL CITRATE, SILDENAFIL, SILDENAFIL POWDER,, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, |
||||
| 456 | 25049796 |
IL |
2 | |
Disease progression, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 457 | 25049830 |
US |
55 | 2 |
Disease progression, |
||||
OXALIPLATIN, FLUOROURACIL, |
||||
| 458 | 25050141 |
SG |
77 | 2 |
Disease progression, |
||||
TRASTUZUMAB, |
||||
| 459 | 25050215 |
IN |
62 | 2 |
Disease progression, Hepatic cirrhosis, |
||||
ADO-TRASTUZUMAB EMTANSINE, |
||||
| 460 | 25050294 |
US |
2 | |
Emphysema, Disease progression, |
||||
IPRATROPIUM BROMIDE AND ALBUTEROL, |
||||
| 461 | 25050374 |
SK |
2 | |
Disease progression, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 462 | 25050649 |
BR |
||
Acute pulmonary oedema, Cardiac failure congestive, Disease progression, Acute respiratory failure, Cardio-respiratory arrest, |
||||
INOTERSEN, |
||||
| 463 | 25051181 |
77 | ||
Myeloproliferative neoplasm, Disease progression, Off label use, |
||||
RUXOLITINIB, ALPRAZOLAM, CLOPIDOGREL, CLOPIDOGREL BISULFATE, MELATONIN, |
||||
| 464 | 25051185 |
CA |
2 | |
Liver disorder, Bone disorder, Disease progression, |
||||
FULVESTRANT, |
||||
| 465 | 25051237 |
JP |
8 | 1 |
Disease progression, Gastric haemorrhage, Nausea, Decreased appetite, Neutrophil count decreased, Platelet count decreased, White blood cell count decreased, Lymphocyte count decreased, Nausea, Underdose, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, FAM-TRASTUZUMAB DERUXTECAN-NXKI, PALONOSETRON HYDROCHLORIDE, |
||||
| 466 | 25051640 |
IL |
2 | |
Disease progression, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 467 | 25051816 |
SK |
2 | |
Disease progression, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 468 | 25057786 |
65 | 2 | |
Breast cancer female, Metastases to bone, Disease progression, |
||||
CAPECITABINE, CAPECITABINE, LORAZEPAM, MORPHINE SULFATE, MORPHINE SULFATE, NALOXONE HYDROCHLORIDE NASAL, NALOXONE HYDROCHLORIDE, FAMOTIDINE, |
||||
| 469 | 25043517 |
IN |
21 | 1 |
Disease progression, Drug ineffective for unapproved indication, |
||||
ETOPOSIDE, ETOPOSIDE, BLEOMYCIN, BLEOMYCIN SULFATE, BLEOMYCIN, BLEOMYCIN SULFATE, CISPLATIN, CISPLATIN, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, |
||||
| 470 | 25043518 |
US |
64 | 1 |
Non-small cell lung cancer, Peripheral T-cell lymphoma unspecified, Disease progression, Drug ineffective for unapproved indication, |
||||
ETOPOSIDE, DOXORUBICIN, PREDNISONE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, RITUXIMAB, PEMBROLIZUMAB, FLUDARABINE PHOSPHATE, BRENTUXIMAB VEDOTIN, AXICABTAGENE CILOLEUCEL, |
||||
| 471 | 25043669 |
US |
||
Disease progression, |
||||
CAPIVASERTIB, |
||||
| 472 | 25043729 |
IN |
50 | 2 |
Disease progression, |
||||
PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF, |
||||
| 473 | 25043747 |
NL |
11 | |
Gastrointestinal fistula, Tumour rupture, Hepatic sarcoma, Disease progression, Off label use, |
||||
PONATINIB HYDROCHLORIDE, |
||||
| 474 | 25043923 |
PK |
76 | 2 |
Disease progression, |
||||
BEVACIZUMAB, |
||||
| 475 | 25044023 |
IQ |
2 | |
Disease progression, |
||||
RITUXIMAB, RITUXIMAB, RITUXIMAB, ETOPOSIDE PHOSPHATE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN, PREDNISONE, IFOSFAMIDE, CARBOPLATIN, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, OXALIPLATIN, |
||||
| 476 | 25044070 |
JP |
65 | 2 |
Hypocalcaemia, Metastases to bone, Disease progression, Drug ineffective, |
||||
LETROZOLE, LETROZOLE TABLETS, LAPATINIB, DENOSUMAB, |
||||
| 477 | 25044143 |
IE |
52 | 1 |
Disease progression, |
||||
BEVACIZUMAB, |
||||
| 478 | 25044211 |
PK |
54 | 2 |
Disease progression, |
||||
TRASTUZUMAB, |
||||
| 479 | 25044215 |
PK |
34 | 2 |
Disease progression, |
||||
TRASTUZUMAB, |
||||
| 480 | 25044288 |
IQ |
67 | 2 |
Disease progression, Therapy non-responder, |
||||
RITUXIMAB, OXALIPLATIN, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, |
||||
| 481 | 25044357 |
US |
||
Disease progression, |
||||
OCRELIZUMAB, |
||||
| 482 | 25044383 |
IQ |
44 | 2 |
Disease progression, |
||||
RITUXIMAB, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, CISPLATIN, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN, PREDNISONE, IFOSFAMIDE, CARBOPLATIN, PLATINUM, |
||||
| 483 | 25044722 |
US |
||
Disease progression, |
||||
OSILODROSTAT, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, ERGOCALCIFEROL, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, GABAPENTIN, SERTRALINE HYDROCHLORIDE, |
||||
| 484 | 25044879 |
BR |
52 | 2 |
Disease progression, |
||||
TRASTUZUMAB, TRASTUZUMAB, ANASTROZOLE, ANASTROZOLE TABLETS, ANASTROZOLE, ANASTROZOLE TABLETS, |
||||
| 485 | 25044974 |
TR |
2 | |
Disease progression, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 486 | 25045008 |
JP |
65 | 2 |
Metastases to bone, Disease progression, Hypocalcaemia, Dry mouth, Electrocardiogram QT prolonged, |
||||
ANASTROZOLE, ANASTROZOLE TABLETS, FULVESTRANT, LETROZOLE, LETROZOLE TABLETS, CAPECITABINE, TRASTUZUMAB, DENOSUMAB, LAPATINIB, |
||||
| 487 | 25045478 |
IL |
2 | |
Disease progression, Therapy non-responder, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 488 | 25045513 |
CA |
70 | 1 |
Renal cell carcinoma, Disease progression, |
||||
LENALIDOMIDE, |
||||
| 489 | 25045815 |
|||
Cholangiocarcinoma, Disease progression, |
||||
PEMIGATINIB, |
||||
| 490 | 25045843 |
US |
32 | 2 |
Drug ineffective, Disease progression, |
||||
DOXORUBICIN, IFOSFAMIDE, |
||||
| 491 | 25045844 |
FR |
14 | 1 |
Thrombocytopenia, Hypertension, Diarrhoea, Proteinuria, Disease progression, Drug ineffective, Off label use, |
||||
ETOPOSIDE, ETOPOSIDE, ETOPOSIDE, ETOPOSIDE, AXITINIB, AXITINIB, AXITINIB, AXITINIB, |
||||
| 492 | 25046151 |
|||
Cholangiocarcinoma, Disease progression, |
||||
PEMIGATINIB, |
||||
| 493 | 25046187 |
IT |
67 | 2 |
Disease progression, Drug ineffective, |
||||
DOXORUBICIN, DACARBAZINE, |
||||
| 494 | 25046925 |
IN |
2 | |
Disease progression, |
||||
TRASTUZUMAB, PERTUZUMAB, FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 495 | 25047018 |
AT |
27 | 2 |
Infection, CSF oligoclonal band present, Spinal disorder, Disease progression, Pleocytosis, Anti-aquaporin-4 antibody positive, Maternal exposure during pregnancy, |
||||
RITUXIMAB, NATALIZUMAB, |
||||
| 496 | 25047042 |
US |
||
Disease progression, |
||||
BEVACIZUMAB-AWWB, |
||||
| 497 | 25047083 |
SE |
14 | 1 |
Disease progression, Drug ineffective, |
||||
PREDNISONE, PREDNISONE, DOXORUBICIN, DOXORUBICIN, ETOPOSIDE, ETOPOSIDE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CONTINUOUS SPRAY, ANTI-PRURITIC, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, HYDROCORTISONE LOTION KIT, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE CREAM 1%, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 498 | 25047258 |
IT |
83 | 2 |
Diffuse large B-cell lymphoma, Disease progression, |
||||
LENALIDOMIDE, RITUXIMAB, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, POLATUZUMAB VEDOTIN, OXALIPLATIN, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, ACYCLOVIR, SULFAMETHOXAZOLE AND TRIMETHOPRIM, RAMIPRIL, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, CARVEDILOL, SIMVASTATIN, SERTRALINE, ALLOPURINOL, |
||||
| 499 | 25047764 |
IL |
2 | |
Disease progression, Therapy non-responder, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 500 | 25048032 |
AU |
||
Disease progression, |
||||
OSIMERTINIB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28